DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced the publication of data from a single center, real-world study with one-year clinical follow-up of patients selected from the ...
Mainstay Medical Holdings plc has won U.S. FDA approval for its Reactiv8 implantable neurostimulation device. The company is eyeing a commercial launch of the system in early 2021. The FDA approved ...
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota
DUBLIN--(BUSINESS WIRE)--Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative ...
A study has found that restorative neurostimulation continues to be effective in treating low-back pain caused by multifidus dysfunction after three years. This type of dysfunction occurs when the ...
“This is a totally new way of treating back pain,” said Prentiss Lawson Jr., M.D., an associate professor in the UAB Department of Anesthesiology and Perioperative Medicine and program director of the ...
Low back pain is the biggest musculoskeletal issue affecting the world today. At any given moment, up to 33 percent of the population is dealing with low back pain. It is one of the most common ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results